Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China

BACKGROUND: The burden of pneumococcal disease in China is high, and a 13-valent pneumococcal conjugate vaccine (PCV13) recently received regulatory approval and is available to Chinese infants. PCV13 protects against the most prevalent serotypes causing invasive pneumococcal disease (IPD) in China,...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Kunling, Wasserman, Matthew, Liu, Dongdong, Yang, Yong-Hong, Yang, Junfeng, Guzauskas, Greg F., Wang, Bruce C. M., Hilton, Betsy, Farkouh, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059448/
https://www.ncbi.nlm.nih.gov/pubmed/30044865
http://dx.doi.org/10.1371/journal.pone.0201245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059448/
https://www.ncbi.nlm.nih.gov/pubmed/30044865
http://dx.doi.org/10.1371/journal.pone.0201245

Ejemplares similares